Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 7/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1511934 | 0.92 | GRM2 (0.35) | IDH1CNR2GRM2DRD4CYP2C19 | |
| SCHEMBL1765301 | 0.85 | IDH1 (0.38) | IDH1CNR2GRM2SMN1; SMN2NPSR1 | |
| SCHEMBL12649282 | 0.83 | SMN1; SMN2 (0.36) | IDH1CNR2GRM2DRD4CYP2C19 | |
| SCHEMBL1511800 | 0.82 | GRM2 (0.35) | IDH1CNR2GRM2DRD4CYP2C19 | |
| SCHEMBL1512637 | 0.82 | DRD4 (0.37) | IDH1CNR2GRM2DRD4CYP2C19 | |
| SCHEMBL2454633 | 0.78 | GRM2 (0.41) | IDH1CNR2GRM2SMN1; SMN2NPSR1 | |
| SCHEMBL1511916 | 0.78 | GRM2 (0.41) | IDH1CNR2GRM2SMN1; SMN2NPSR1 | |
| SCHEMBL1245592 | 0.77 | GRM2 (0.52) | IDH1GRM2CYP2C19SMN1; SMN2NPSR1 | |
| SCHEMBL1511669 | 0.76 | GRM2 (0.39) | IDH1CNR2GRM2SMN1; SMN2NPSR1 | |
| SCHEMBL1512867 | 0.76 | KDM4E (0.34) | IDH1CNR2GRM2MCHR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124661-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. | 2011-05-26 | — | — | US | claimed |
| US-20110124661-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. | 2011-05-26 | — | — | US | disclosed |
| US-20110124661-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124661-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | GRM2, GRM1, GRM3 | IDH1 1046/4885CNR2 95/4885GRM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.